Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, Stomrud E, Tideman P, Ohlsson T, Jögi J, Johnson K, Sperling R, Dore V, Masters CL, Rowe C, Visser D, van Berckel BNM, van der Flier WM, Baker S, Jagust WJ, Wiste HJ, Petersen RC, Jack CR, Hansson O. · 2022
Read Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. by Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, Stomrud E, Tideman P, Ohlsson T, Jögi J, Johnson K, Sperling R, Dore V, Masters CL, Rowe C, Visser D, van Berckel BNM, van der Flier WM, Baker S, Jagust WJ, Wiste HJ, Petersen RC, Jack CR, Hansson O. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9671808.txt.
Introduction
Ossenkoppele and co-authors test whether cognitively sharp people with both Alzheimer hallmarks on PET scans will decline. Amyloid plaques and tau tangles mark the disease in the brain. Some people carry both marks yet think clearly for years. Their true risk was a major open question.
The multicenter PET study covered 1,325 unimpaired individuals in total. Groups were split by amyloid and tau scan results. People positive for both marks faced far higher risk ahead. Their odds of moving to mild cognitive impairment rose steeply. Decline also ran faster in those with tau in wider brain zones. Amyloid alone, without tau, gave a much smaller lift in risk. Both dual positive groups slid faster than the amyloid only group. The authors tie the forecast to a 3 to 5 year window. They call dual scan proof a strong short term warning sign.
Catalog record
| CREATOR | Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, Stomrud E, Tideman P, Ohlsson T, Jögi J, Johnson K, Sperling R, Dore V, Masters CL, Rowe C, Visser D, van Berckel BNM, van der Flier WM, Baker S, Jagust WJ, Wiste HJ, Petersen RC, Jack CR, Hansson O. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline By Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, Ruben Smith, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Pontus Tideman, Tomas Ohlsson, Jonas Jögi, Keith Johnson, Reisa Sperling Published in: Nature Medicine DOI: 10.1038/s41591-022-02049-x ABSTRACT A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer’s disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multicenter amyloid and tau positron emission tomography (PET) study (n = 1,325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A+) and tau PET-positive (T+) in the medial temporal lobe (A+TMTL+) and/or in the temporal neocortex (A+TNEO-T+) and compared them with A+T− and A−T− groups. Cox proportional-hazards models showed a substantially increased risk for progression to mild cognitive impairment in the A+TNEO-T+ (hazard ratio (HR) = 19.2, 95% confidence interval (CI) = 10.9–33.7), A+TMTL+ (HR = 14.6, 95% CI = 8.1–26.4) and A+T− (HR = 2.4, 95% CI = 1.4–4.3) groups versus the A−T− (reference) group. Both A+TMTL+ (HR = 6.0, 95% CI = 3.4–10.6) and A+TNEO-T+ (HR = 7.9, 95% CI = 4.7–13.5) groups also showed faster clinical progression to mild cognitive impairment than the A+T− group. Linear mixed-effect models indicated that the A+TNEO-T+ (β = −0.056 ± 0.005, T = −11.55, P < 0.001), A+TMTL+ (β = −0.024 ± 0.005, T = −4.72, P < 0.001) and A+T− (β = −0.008 ± 0.002, T = −3.46, P < 0.001) groups showed significantly faster longitudinal global cognitive decline compared to the A−T− (reference) group (all P < 0.001). Both A+TNEO-T+ (P < 0.001) and A+TMTL+ (P = 0.002) groups also progressed faster than the A+T− group. In summary, evidence of advanced Alzheimer’s disease pathological changes provided by a combination of abnormal amyloid and tau PET examinations is strongly associated with short-term (that is, 3–5 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance. MAIN Alzheimer’s disease (AD) is neuropathologically characterized by the presence of amyloid-β (Αβ) plaques and tau neurofibrillary tangles. Although the two most well-established diagnostic criteria for AD both acknowledge the importance of Αβ and tau pathology in AD pathogenesis1, an important distinction is that the National Institute on Aging and Alzheimer’s Association (NIA-AA) criteria2 define AD by its biological features (that is, the presence of Αβ and tau pathology) irrespective of the clinical syndrome, whereas the International Working Group (IWG) criteria3 require the presence of objective cognitive impairment (mild cognitive impairment (MCI) or dementia) in conjunction with positive AD biomarkers. Consequently, there is fundamental disagreement between the criteria about the nomenclature for cognitively unimpaired individuals who harbor one or both AD hallmark neuropathological features. For example, a cognitively unimpaired individual with positive Αβ (Α+) and tau (T+) biomarkers is classified as ‘preclinical AD’ by the NIA-AA criteria2, while the IWG criteria3 would label such an individual ‘at risk for progression to AD’ (Fig. 1).Fig. 1NIA-AA versus IWG criteria.Differences in the nomenclature of cognitively unimpaired individuals with (+) or without (−) in vivo biomarker evidence of Aβ (A) and tau (T) pathology in the NIA-AA versus IWG criteria for AD. Note that for the IWG criteria, the presumed ‘risk for progression’ level rises when both A and T biomarkers are positive. Aside from philosophical differences (for example, according to the IWG criteria the term AD should be restricted to symptomatic individuals), the discrepancy between the NIA-AA and IWG can be explained by at least two factors. First, according to the IWG criteria, currently available Αβ and tau biomarkers show ‘low predictive accuracy’ for development of cognitive symptoms. For Αβ biomarkers alone this may indeed be the case4,5, although PET studies with long follow-ups (approximately 10 years) indicate substantial Αβ-associated risk for cognitive decline6, dementia7 and death7. For tau biomarkers, however, the clinicopathological correlates are much stronger than for Αβ biomarkers8,9, even in asymptomatic individuals10,11. Second, most prognostic studies to date are based on cerebrospinal fluid (CSF) biomarkers of soluble phospho-tau levels, which is an early marker of AD pathology12,13. In contrast, the more recently introduced tau PET technique measures more advanced pathological changes since it captures insoluble tau aggregates14,15. Although tau PET positivity in the neocortex is relatively rare among cognitively unimpaired individuals (approximately 5–10%16–18), its presence is strongly associated with worse cross-sectional10,19–22 and longitudinal11,23–32 cognitive outcomes. However, large-scale longitudinal studies with combinations of amyloid PET and tau PET biomarker profiles as predictors of clinical progression among cognitively unimpaired individuals are lacking33. In addition to addressing the differences between the NIA-AA and IWG criteria, early detection of AD pathological changes may be key for future interventions with disease-modifying treatments since these will most likely be cost-effective and show the most favorable benefit versus risk ratio when specifically targeting preclinical populations with AD that are most likely to experience substantial cognitive deterioration in the short term (that is, 3–5 years). Therefore, the aim of the current multicenter study was to examine clinical progression to MCI or dementia and assess cognitive decline in cognitively unimpaired individuals with different Αβ (A) and tau (T) biomarker profiles as defined by PET at baseline. We divided A+T+ individuals into medial temporal lobe (MTL) only (A+TMTL+) and temporal neocortical (A+TNEO-T+) T+ groups to additionally investigate the impact of more advanced tau pathological changes on clinical progression. RESULTS Participants We included 1,325 cognitively unimpaired participants from 7 cohorts, of whom 843 (63.6%) were A−T−, 328 (24.8%) A+T−, 55 (4.2%) A+TMTL+ and 65 (4.9%) A+TNEO-T+ (see Table 1 and Supplementary Table 1 for a breakdown by cohort). All biomarker-positive groups were older and had lower baseline Mini-Mental State Examination (MMSE) scores compared to the A−T− group (all P < 0.001). There were no sex differences between groups. The average follow-up duration was 41.8 ± 18.9 months. The A−T+ group was considerably smaller than the other groups (n = 34; Extended Data Table 1), hence their results are only reported in Extended Data Fig. 1.Table 1Participant characteristicsA−T−A+T−A+TMTL+A+TNEO-T+Pn8433285565Age, years68.6 ± 9.675.5 ± 8.275.6 ± 6.676.4 ± 6.8<0.001aSex, n (%) male424 (50.3)164 (50.0)24 (43.6)31 (47.7)0.822Education, years14.7 ± 3.114.6 ± 3.113.7 ± 3.813.9 ± 3.50.02bFollow-up duration, months43.0 ± 18.940.1 ± 17.639.0 ± 16.536.4 ± 14.90.004cFollow-up visits, number4.1 ± 1.54.1 ± 1.44.0 ± 1.33.6 ± 1.20.07MMSE, baseline score29.0 ± 1.028.7 ± 1.328.3 ± 1.528.2 ± 1.3<0.001dProgression to MCI, n (%)26 (8.9%)26 (3.3%)25 (49.0%)32 (53.3%)<0.001Progression to all-cause dementia, n (%)4 (0.5%)3 (1.0%)2 (3.9%)12 (20.0%)<0.001P values from two-sided statistical tests were reported. ANOVAs were used for continuous variables and chi-squared tests were used for categorical variables. Post-hoc tests were adjusted using Bonferroni correction.aA+TNEO-T+ and A+TMTL+ and A+T− > A−T− b post-hoc tests revealed no significant group differences, cA−T− > A+TNEO-T+, dA+TNEO-T+, A+TMTL+ and A+T− < A−T− and A+TNEO-T+ < A+ T-. Clinical progression to MCI During the clinical follow-up, 26 out of 781 (3.3%) of A−T−, 26 out of 292 (8.9%) of A+T−, 25 out of 51 (49.0%) of A+TMTL+ and 32 out of 60 (53.3%) of A+TNEO-T+ participants progressed to MCI or dementia. Among A+TNEO-T+ individuals, the